<DOC>
	<DOCNO>NCT01402986</DOCNO>
	<brief_summary>The purpose study determine whether addition tralokinumab standard asthma medication effective treatment adult asthma .</brief_summary>
	<brief_title>A Safety Efficacy Study Tralokinumab Adults With Asthma</brief_title>
	<detailed_description>Interleukin-13 ( IL-13 ) key mediator pathogenesis establish asthmatic disease . Tralokinumab human monoclonal antibody block IL-13 , may result improve control asthma . This study determine whether addition tralokinumab standard asthma medication result reduce rate asthma exacerbation subject severe asthma .</detailed_description>
	<mesh_term>Asthma</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>Age 1875 year Body mass index ( BMI ) 1640 kilogram per square meter ( kg/m^2 ) Visit 1 Uncontrolled severe asthma A chest xray abnormality Females childbearing potential sexually active nonsterilized male partner must use highly effective contraception Day 1 Nonsterilized male sterilize male less equal ( = &lt; ) 1 year postvasectomy sexually active female partner childbearing potential must use highly effective method contraception Employee clinical study site individual directly involve conduct study , immediate family member individual Pregnant breastfeed woman Any respiratory disease Previously take tralokinumab ( study drug ) Current smoker history smoking would 1 pack per day 10 year Known immune deficiency History cancer Hepatitis B , C Human Immunodeficiency Virus ( HIV ) Any disease may cause complication whilst take study drug .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Asthma</keyword>
	<keyword>Tralokinumab</keyword>
	<keyword>CAT-354</keyword>
</DOC>